CoChat
Sign Up
Cited by 212

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

The mast cell and allergic diseases: role in pathogenesis and implications for therapy

Brown, J. M., Wilson, T. M., Metcalfe, D. D.·2008·Clinical & Experimental Allergy
DOI 10.1111/j.1365-2222.2007.02886.x
Open this paper in CoChat — free account

Abstract

Summary: Mast cells have long been recognized for their role in the genesis of allergic inflammation; and more recently for their participation in innate and acquired immune responses. Mast cells reside within tissues including the skin and mucosal membranes, which interface with the external environment; as well as being found within vascularized tissues next to nerves, blood vessels and glandular structures. Mast cells have the capability of reacting both within minutes and over hours to specific stimuli, with local and systemic effects. Mast cells express the high affinity IgE receptor (FcɛRI) and upon aggregation of FcɛRI by allergen‐specific IgE, mast cells release and generate biologically active preformed and newly synthesized mediators which are involved in many aspects of allergic inflammation. While mast cells have been well documented to be essential for acute allergic reactions, more recently the importance of mast cells in reacting through pattern recognition receptors in innate immune responses has become recognized. Moreover, as our molecular understanding of the mast cell has evolved, novel targets for modulation have been identified with promising therapeutic potential.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2222.2007.02886.x

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 165

  1. 10.1016/0092-8674(90)90304-W · DOI
  2. 10.1016/j.jaci.2004.04.046 · DOI
  3. 10.1038/nri1782 · DOI
  4. 10.1016/S0002-9440(10)62055-X · DOI · Paper page
  5. 10.1182/blood.V52.2.447.447 · DOI · Paper page
  6. 10.1159/000236955 · DOI
  7. Padawer J., 1974, Mast cells, extended lifespan and lack of granule turnover under normal in vivo conditions, 20, 269
  8. 10.1016/S0161-5890(02)00077-9 · DOI
  9. Woolhiser MR, 2004, Activation of human mast cells by aggregated IgG through FcgammaRI, additive effects of C3a, 110, 172
  10. 10.1002/1521-4141(200111)31:11<3298::AID-IMMU3298>3.0.CO;2-U · DOI
  11. 10.1165/rcmb.2006-0197OC · DOI
  12. 10.1016/j.coi.2006.11.006 · DOI · Paper page
  13. 10.1073/pnas.96.14.8080 · DOI
  14. 10.1136/gut.2004.054650 · DOI
  15. 10.1046/j.1365-2222.2001.01069.x · DOI
  16. 10.1016/S1471-4906(03)00058-9 · DOI
  17. 10.1038/365340a0 · DOI
  18. 10.1093/intimm/7.4.525 · DOI
  19. 10.1111/j.1398-9995.2005.00823.x · DOI
  20. 10.1136/thx.2006.062141 · DOI
  21. 10.1096/fj.03-0041fje · DOI
  22. 10.1007/s11882-005-0086-9 · DOI
  23. 10.1056/NEJMoa012705 · DOI
  24. 10.4049/jimmunol.176.3.1860 · DOI
  25. 10.1164/rccm.200409-1220OC · DOI
  26. Brightling CE, 2005, Differential expression of CCR3 and CXCR3 by human lung and bone marrow‐derived mast cells, implications for tissue mast cell migration, 77, 759
  27. 10.1016/j.jaci.2006.02.039 · DOI
  28. 10.1164/rccm.200603-394OC · DOI
  29. 10.4049/jimmunol.176.2.1238 · DOI
  30. Page S, 2001, Human mast cell and airway smooth muscle cell interactions, implications for asthma, 281, L1313
  31. 10.1046/j.1365-2222.1999.00580.x · DOI
  32. 10.1034/j.1398-9995.2002.203545.x · DOI
  33. 10.1172/JCI113855 · DOI
  34. 10.1164/ajrccm.164.10.2010096 · DOI
  35. Thangam EB, 2005, Airway smooth muscle cells enhance C3a‐induced mast cell degranulation following cell‐cell contact, FASEB J, 19, 798
  36. 10.1186/1465-9921-6-19 · DOI
  37. 10.1183/09031936.02.00275802 · DOI
  38. 10.1111/j.1365-2222.2003.01827.x · DOI
  39. 10.1111/j.0105-2896.2004.00215.x · DOI · Paper page
  40. Bradding P, 1994, Interleukin‐4, ‐5, and ‐6 and tumor necrosis factor‐alpha in normal and asthmatic airways, evidence for the human mast cell as a source of these cytokines, 10, 471
  41. 10.1164/ajrccm/147.3.697 · DOI
  42. 10.1164/ajrccm/147.3.684 · DOI
  43. Bradding P., 2003, The role of the mast cell in asthma, a reassessment, 3, 45
  44. 10.1136/thorax.57.8.677 · DOI
  45. 10.1016/j.jaci.2004.10.004 · DOI
  46. 10.1016/j.jaci.2004.11.037 · DOI
  47. 10.1111/j.1365-2222.2004.01975.x · DOI
  48. 10.1111/j.1365-2222.2006.02431.x · DOI
  49. 10.1016/S0002-9440(10)65377-1 · DOI
  50. 10.1084/jem.20062211 · DOI
  51. 10.1006/cimm.1994.1272 · DOI
  52. 10.1002/(SICI)1521-4141(199803)28:03<844::AID-IMMU844>3.0.CO;2-4 · DOI
  53. 10.1002/eji.1830261036 · DOI
  54. Nakae S, 2006, Mast cells enhance T cell activation, importance of mast cell costimulatory molecules and secreted TNF, 176, 2238
  55. 10.1016/j.jaci.2005.07.015 · DOI
  56. 10.1016/S1074-7613(01)00159-5 · DOI
  57. 10.1183/09031936.05.00091704 · DOI
  58. Matsuda K, 2005, Monomeric IgE enhances human mast cell chemokine production, IL-4 augments and dexamethasone suppresses the response, 116, 1357
  59. 10.1056/NEJM198902023200502 · DOI
  60. 10.1056/NEJM199110103251504 · DOI
  61. 10.1084/jem.186.3.449 · DOI
  62. 10.1084/jem.192.3.455 · DOI
  63. 10.4049/jimmunol.172.10.6398 · DOI
  64. 10.1016/j.jaci.2004.08.043 · DOI
  65. 10.1111/j.1365-2222.1995.tb01023.x · DOI
  66. 10.1159/000234024 · DOI
  67. 10.1073/pnas.83.12.4464 · DOI
  68. 10.1016/S0091-6749(96)70073-8 · DOI
  69. Saitåo H, 2005, Mast cells in allergic diseases, 10.1159/isbn.978-3-318-01232-3 · DOI
  70. 10.1067/mai.2000.108107 · DOI
  71. 10.1056/NEJM198406213102502 · DOI
  72. Freeland HS, 1989, Leukotriene B4 as a mediator of early and late reactions to antigen in humans, the effect of systemic glucocorticoid treatment in vivo, 83, 634
  73. 10.1016/0091-6749(92)90293-B · DOI
  74. 10.1111/j.1398-9995.1985.tb04147.x · DOI
  75. 10.1016/S0091-6749(97)70125-8 · DOI
  76. 10.1159/000024054 · DOI
  77. 10.1164/ajrccm.161.5.9908028 · DOI
  78. 10.1016/j.jaci.2006.04.037 · DOI
  79. 10.1073/pnas.91.9.3739 · DOI
  80. 10.1002/eji.1830270925 · DOI
  81. 10.1046/j.1365-2222.2000.00906.x · DOI
  82. 10.1046/j.1365-2567.2000.00984.x · DOI
  83. 10.1007/s004030050189 · DOI
  84. 10.1046/j.1365-2133.1997.01831.x · DOI
  85. 10.1111/j.1398-9995.2004.00628.x · DOI
  86. Steinhoff M, 2003, Proteinase‐activated receptor‐2 mediates itch, a novel pathway for pruritus in human skin, 23, 6176
  87. 10.1007/s00403-005-0542-3 · DOI
  88. 10.1111/j.1398-9995.2005.00879.x · DOI
  89. 10.1172/JCI24274 · DOI
  90. 10.1111/1523-1747.ep12330326 · DOI
  91. 10.1016/j.jneuroim.2004.12.019 · DOI
  92. 10.1067/mai.2003.1477 · DOI
  93. 10.1016/j.jaci.2006.02.026 · DOI · Paper page
  94. Schwartz LB., 2004, Effector cells of anaphylaxis, mast cells and basophils, 257, 65
  95. Okayama Y, 2000, Expression of a functional high‐affinity IgG receptor, Fc gamma RI, on human mast cells, up-regulation by IFN-gamma, 164, 4332
  96. 10.1007/BF02592981 · DOI
  97. 10.1002/0470861193.ch11 · DOI
  98. 10.1152/physrev.2000.80.4.1669 · DOI
  99. 10.1172/JCI25426 · DOI
  100. 10.1073/pnas.92.23.10560 · DOI
  101. 10.1016/0163-7258(88)90085-X · DOI
  102. Donlon MA, 1988, Release of biological mediators in response to acute radiation injury, Fund Appl Toxicol, 11, 572
  103. 10.7326/0003-4819-32-2-207 · DOI
  104. 10.4049/jimmunol.179.5.3276 · DOI
  105. 10.1084/jem.188.9.1587 · DOI
  106. 10.1067/mai.2002.123302 · DOI
  107. Abelson MB., 2001, Allergic diseases of the eye
  108. Friedlaender MH., 1991, Current concepts in ocular allergy, Ann Allergy, 67, 5
  109. Ono SJ, 2005, Allergic conjunctivitis, update on pathophysiology and prospects for future treatment, 115, 118
  110. Allansmith MR., 1990, Immunology of the external ocular tissues, J Am Optom Assoc, 61, S16
  111. 10.1111/j.1365-2222.1997.tb01179.x · DOI
  112. 10.1097/00130832-200210000-00009 · DOI
  113. 10.1067/mai.2001.117591 · DOI
  114. 10.1385/IR:33:3:213 · DOI
  115. 10.1016/j.jaci.2006.04.005 · DOI
  116. 10.2174/1568010023344733 · DOI
  117. 10.1016/0092-8674(91)90556-E · DOI · Paper page
  118. 10.1016/j.ejphar.2004.06.033 · DOI
  119. 10.1038/sj.bjp.0701703 · DOI
  120. Nials AT, 1994, Formoterol on airway smooth muscle and human lung mast cells, a comparison with salbutamol and salmeterol, 251, 127
  121. 10.1016/S0306-3623(98)00080-9 · DOI
  122. 10.1016/S0091-6749(99)70269-1 · DOI
  123. Howarth PH, 1985, Influence of albuterol, cromolyn sodium and ipratropium bromide on the airway and circulating mediator responses to allergen bronchial provocation in asthma, Am Rev Respir Dis, 132, 986
  124. 10.1016/j.jaci.2004.06.032 · DOI
  125. 10.1016/j.jaci.2004.07.064 · DOI
  126. Elsner J, 2004, Chemokine receptor antagonists, a novel therapeutic approach in allergic diseases, 59, 1243
  127. 10.1165/rcmb.2002-0155OC · DOI
  128. De Lucca GV., 2006, Recent developments in CCR3 antagonists, Curr Opin Drug Discov Devel, 9, 516
  129. 10.1096/fj.06-6016fje · DOI
  130. 10.4049/jimmunol.167.8.4261 · DOI
  131. 10.1016/j.jaci.2004.04.005 · DOI
  132. 10.1136/thx.2006.060319 · DOI
  133. 10.1002/eji.200637024 · DOI
  134. 10.1084/jem.20042085 · DOI
  135. Daeron M, 1982, Biochemical analysis of glucocorticoid‐induced inhibition of IgE‐mediated histamine release from mouse mast cells, J Immunol, 129, 1212, 10.4049/jimmunol.129.3.1212 · DOI
  136. 10.1016/S0091-6749(98)70064-8 · DOI
  137. 10.1111/j.1365-2249.2004.02510.x · DOI
  138. Robin JL, 1985, Regulation of mediator release from mouse bone marrow‐derived mast cells by glucocorticoids, J Immunol, 135, 2719, 10.4049/jimmunol.135.4.2719 · DOI
  139. 10.1016/S0002-9343(97)00240-4 · DOI
  140. 10.1038/sj.bjp.0704617 · DOI
  141. Finotto S, 1997, Glucocorticoids decrease tissue mast cell number by reducing the production of the c‐kit ligand, stem cell factor, by resident cells, in vitro and in vivo evidence in murine systems, 99, 1721
  142. 10.1124/mol.104.008607 · DOI
  143. Hiragun T, 2006, Cutting edge, dexamethasone negatively regulates Syk in mast cells by up-regulating SRC-like adaptor protein, 177, 2047
  144. 10.1046/j.1365-2745.2002.01418.x · DOI
  145. 10.2500/aap.2006.27.2861 · DOI
  146. 10.1016/j.jaci.2005.01.040 · DOI
  147. 10.1016/j.ejphar.2005.12.054 · DOI
  148. Dominguez C, 2005, p38 MAP kinase inhibitors, many are made, but few are chosen, 8, 421
  149. 10.2174/138945006777435353 · DOI
  150. Houslay MD, 2005, Keynote review, phosphodiesterase-4 as a therapeutic target, 10, 1503
  151. Kanaoka Y, 2004, Cysteinyl leukotrienes and their receptors, cellular distribution and function in immune and inflammatory responses, 173, 1503
  152. Mellor EA, 2003, Expression of the type 2 receptor for cysteinyl leukotrienes (CysLT2R) by human mast cells, functional distinction from CysLT1R, 100, 11589
  153. 10.1073/pnas.141221498 · DOI
  154. Bakker RA, 2001, Histamine H(1)‐receptor activation of nuclear factor‐kappa B, roles for G beta gamma- and G alpha(q/11)-subunits in constitutive and agonist-mediated signaling, 60, 1133
  155. 10.1124/jpet.102.046581 · DOI
  156. 10.1164/ajrccm.164.supplement_2.2106058 · DOI
  157. 10.4049/jimmunol.169.9.5315 · DOI
  158. 10.2174/092986706775476070 · DOI
  159. 10.1016/j.pupt.2004.09.032 · DOI
  160. Arimura A, 2001, Prevention of allergic inflammation by a novel prostaglandin receptor antagonist, S‐5751, J Pharmacol Exp Ther, 298, 411, 10.1016/S0022-3565(24)29398-8 · DOI
  161. 10.1016/j.molmed.2006.02.005 · DOI
  162. Ly TW, 2005, Small‐molecule CRTH2 antagonists for the treatment of allergic inflammation, an overview, 14, 769
  163. 10.2174/15680266106061427 · DOI
  164. 10.1038/nri1460 · DOI
  165. 10.1517/13543784.13.2.107 · DOI

Cited by

Sorted by citations

See all 212

Metadata

Authors
Brown, J. M., Wilson, T. M., & Metcalfe, D. D.
Venue
Clinical & Experimental Allergy
Publisher
Wiley
Published
2007-11-21
Volume
38
Issue
1
Pages
4-18
ISSN
  • 0954-7894
  • 1365-2222
DOI
10.1111/j.1365-2222.2007.02886.x
Cited by
212
References
4
Language
en
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review